The GH-Axis Peptide Stack: CJC-1295, Ipamorelin, Sermorelin, and IGF-1 LR3 in Research Context (2026 Guide)

The somatotropic axis - the hypothalamic-pituitary-IGF-1 signalling cascade that governs growth hormone release - is one of the most actively researched targets in peptide science. CJC-1295, Ipamorelin, Sermorelin, and IGF-1 LR3 aren't interchangeable compounds that all 'raise GH.' They act at fundamentally different nodes of a tightly regulated feedback system, and stacking them without understanding that architecture is how researchers generate confounded data and, in self-experimental contexts, avoidable risk.

Most content covering these peptides treats them like a menu: pick what sounds good, combine freely, report results. This guide does the opposite. It maps each compound to its precise point of action on the GH axis, summarises what the evidence actually shows (with human trials, animal studies, and anecdotal community reports explicitly labelled), and makes the case for why moving downstream toward IGF-1 LR3 is a qualitatively different risk category - not just a more aggressive version of the same intervention.

A hard disclaimer before proceeding: Every compound discussed here, except Sermorelin (which has a US compounding pharmacy pathway) and the GLP-1 class (not covered here), is sold as a research chemical and is not approved by the FDA, MHRA, EMA, or TGA for human therapeutic use. Nothing in this guide is medical advice, and dosing figures cited are drawn from published research protocols, not presented as recommendations. Regulatory status varies significantly by jurisdiction and is covered in detail below.

What Is the GH Axis - and Why Do Researchers Stack Peptides Along It?

The somatotropic axis operates through a layered signalling hierarchy. The hypothalamus releases growth hormone-releasing hormone (GHRH), which acts on somatotroph cells in the anterior pituitary to stimulate GH secretion. Simultaneously, the hypothalamus releases somatostatin (SST), which inhibits GH release and creates the pulsatile pattern characteristic of endogenous GH secretion. Released GH then acts on peripheral tissues - primarily the liver - to stimulate synthesis and secretion of insulin-like growth factor 1 (IGF-1), which mediates many of GH's downstream anabolic and metabolic effects.

The research rationale for stacking peptides at multiple nodes of this axis is mechanistically coherent: GHRH analogs (CJC-1295, Sermorelin) stimulate GH release at the pituitary level, while GH-releasing peptides (GHRPs) like Ipamorelin and GHRP-2 act primarily via the ghrelin receptor (GHS-R1a) to amplify GH pulse amplitude and partially suppress somatostatin tone. Research published in journals including the *Journal of Clinical Endocrinology and Metabolism* has documented synergistic GH release when GHRH and GHRP-class compounds are co-administered - an additive or supra-additive effect that neither compound achieves alone at equivalent doses.

IGF-1 LR3 operates at an entirely different level. It bypasses the pituitary entirely and directly engages IGF-1 receptors in peripheral tissue. That's not a more potent version of GHRH stimulation - it's a different class of intervention with a different risk architecture, discussed separately below.

---

The Four Core Compounds: Chemical Identity and Classification

CJC-1295

CJC-1295 is a synthetic 30-amino acid GHRH analog developed from the native GHRH(1-29) peptide sequence. The most commercially prevalent form incorporates a Drug Affinity Complex (DAC) modification - a lysine residue with a maleimidoproprionic acid attachment that enables covalent bonding to circulating albumin, dramatically extending plasma half-life from approximately 7 minutes (native GHRH) to an estimated 6-8 days. CJC-1295 without DAC (sometimes labelled as Mod GRF 1-29) has a more modest half-life extension to approximately 30 minutes through amino acid substitutions alone. The DAC vs. non-DAC distinction is pharmacologically significant and is frequently mislabelled in the vendor market.

Ipamorelin

Ipamorelin is a synthetic pentapeptide GHRP and selective agonist of the ghrelin receptor (GHS-R1a). It was developed by Novo Nordisk in the 1990s and characterised in early clinical programs before being discontinued from pharmaceutical development. Its defining research characteristic is high selectivity: unlike earlier-generation GHRPs, peer-reviewed pharmacology studies show minimal concomitant elevation of cortisol, prolactin, or ACTH at GH-stimulating doses.

Sermorelin

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of endogenous GHRH (GHRH(1-29)). It was formerly FDA-approved as Geref for pediatric GH deficiency diagnosis and treatment before being voluntarily withdrawn from the market by the manufacturer in 2008. It retains a US compounding pharmacy pathway, which sets it apart from most other peptides in this guide from a regulatory standpoint.

IGF-1 LR3

IGF-1 LR3 (Long R3 IGF-1) is a recombinant analog of human insulin-like growth factor 1. It incorporates an N-terminal 13-amino acid extension and an Arg3 substitution that collectively reduce binding affinity to IGF-binding proteins (IGFBPs) by approximately 1000-fold relative to native IGF-1. This reduces sequestration in the circulation, extending the half-life from under 10 minutes (native IGF-1) to an estimated 20-30 hours and increasing bioavailable free-peptide concentration at receptor sites.

---

Mechanism of Action: How Each Peptide Interfaces With the Somatotropic Axis

CJC-1295: GHRH Receptor Agonism With Sustained Occupancy

CJC-1295 (DAC form) binds and activates the GHRH receptor (GHRHR) on anterior pituitary somatotrophs. Through intracellular cAMP signalling, this stimulates GH gene transcription and secretion. The albumin-binding DAC modification maintains receptor occupancy over days rather than minutes, producing sustained - rather than pulsatile - GH stimulation. Published Phase II trial data (Ionescu and Frohman, *Journal of Clinical Endocrinology and Metabolism*, 2006, n=64) documented mean GH elevations of 2-10 fold and IGF-1 increases of 1.5-3 fold sustained over 2 weeks following single injections. Physiological GH pulsatility is partially preserved because the pituitary retains some capacity for somatostatin-mediated oscillation, but the continuous GHRHR stimulation does attenuate the trough-to-peak ratio compared to endogenous patterns.

Ipamorelin: Selective Ghrelin Receptor Agonism

Ipamorelin activates GHS-R1a receptors in both the pituitary and hypothalamus. At the pituitary, GHS-R1a activation increases intracellular calcium via Gq/11 protein coupling, potentiating GH secretion. In the hypothalamus, GHRP-class compounds partially suppress somatostatin release, reducing the inhibitory brake on GH output. Critically, peer-reviewed pharmacology studies (Raun et al., *European Journal of Endocrinology*, 1998) show Ipamorelin achieves this without meaningful activation of the ACTH-cortisol or prolactin axes at standard research doses - a selectivity profile that distinguishes it from GHRP-2 and Hexarelin.

Sermorelin: Short-Duration GHRH Receptor Activation

Sermorelin's mechanism is essentially identical to CJC-1295 at the receptor level - GHRHR agonism stimulating pituitary GH release. The practical difference is duration: with a plasma half-life of approximately 10-20 minutes, each injection produces a discrete GH pulse that mirrors endogenous pulsatile physiology more closely than DAC-modified CJC-1295. Some researchers consider this a feature rather than a limitation, since it preserves the feedback architecture of the axis.

IGF-1 LR3: Direct Peripheral Receptor Activation, Bypassing Pituitary Regulation

IGF-1 LR3 doesn't interact with the hypothalamic-pituitary axis at all. It binds IGF-1 receptors (IGF-1R) directly in peripheral tissues - skeletal muscle, liver, adipose tissue, and others. IGF-1R is a receptor tyrosine kinase; activation initiates PI3K/Akt and MAPK/ERK signalling cascades that promote cellular proliferation, protein synthesis, and glucose uptake. Because it bypasses the GH-axis feedback loop entirely, IGF-1 LR3 doesn't trigger the same somatostatin-mediated counter-regulation. Its mitogenic signalling at IGF-1R also means it activates the same pathways implicated in cellular proliferation in malignant tissue - a risk that's not theoretical but structurally inherent to its mechanism.

---

The Stacking Rationale: GHRH + GHRP Synergy in Research Literature

The scientific basis for combining a GHRH analog with a GHRP is well-documented in peer-reviewed endocrinology literature predating the research-chemical market. Seminal work by Bowers et al. and subsequent researchers demonstrated that co-administration of GHRH with synthetic GHRPs produces GH release substantially exceeding additive expectations from either compound alone. The proposed mechanisms include:

1. Complementary intracellular signalling (cAMP via GHRHR + calcium via GHS-R1a) producing convergent amplification at the somatotroph

2. GHRP-mediated somatostatin suppression reducing the inhibitory tone that would otherwise blunt GHRH-stimulated GH release

3. Possible hypothalamic GHRH release augmented by GHRP action, creating a dual peripheral and central effect

In research contexts, CJC-1295 + Ipamorelin is the most commonly studied combination in the self-experimental community and is referenced in grey literature as a standard research stack. The mechanistic logic is sound. What's less sound is assuming that maximum GH stimulation is the research objective - sustained supraphysiological GH and IGF-1 elevations carry their own signal, including insulin resistance and acromegaloid soft tissue effects with prolonged use.

The honest research position: GHRH+GHRP co-administration is mechanistically well-supported. The long-term safety profile of sustained combination use in healthy adults is not characterised in controlled human trials.

---

Evidence Summary by Compound: Human Trials, Animal Studies, and Anecdotal Reports

CJC-1295 - Evidence Summary

Human trial evidence: The primary published human pharmacokinetic data comes from Ionescu and Frohman (2006), a Phase II study in 64 healthy adults demonstrating dose-dependent GH and IGF-1 elevation sustained over 14 days following single subcutaneous injections. This is among the strongest human-trial evidence bases for any research-chemical GHRH analog currently on the market.

Animal evidence: Preclinical rodent and non-human primate data support GHRHR agonism, GH/IGF-1 axis activation, and downstream anabolic effects on lean mass and adiposity - consistent with the established pharmacology.

Anecdotal community reports: Forum-sourced self-experimental reports (primarily Reddit, Longecity, and dedicated peptide communities) describe GH-axis effects consistent with the mechanism: improved sleep quality (particularly slow-wave sleep), reduced body fat over 8-12 week protocols, and minor side effects including water retention and injection-site reactions. These reports are uncontrolled, unblinded, and subject to significant confounding.

Ipamorelin - Evidence Summary

Human trial evidence: Novo Nordisk conducted early-stage clinical programs in the 1990s, and pharmacological characterisation papers exist in the peer-reviewed literature. Robust Phase II/III human clinical trial data specifically for body composition or performance outcomes in healthy adults is essentially absent. The selectivity profile (minimal cortisol/prolactin elevation) is documented in published animal and early human pharmacology work.

Animal evidence: Well-characterised in rodent models, including GH pulse data, body composition effects, and bone density outcomes. The Raun et al. (1998) *European Journal of Endocrinology* paper remains a foundational reference.

Anecdotal community reports: Ipamorelin is among the most widely self-experimented GHRPs, with a large volume of community reports describing improved sleep architecture, gradual lean body composition changes over multi-week protocols, and good tolerability with low appetite stimulation compared to GHRP-2 or GHRP-6. As with all self-reports, these carry no evidentiary weight for clinical outcomes.

Sermorelin - Evidence Summary

Human trial evidence: Sermorelin has a legitimate clinical history, including at least one small RCT in adults with GH deficiency, and was used in pediatric diagnostic and therapeutic contexts before market withdrawal. Evidence for anti-aging or body composition benefits specifically in healthy aging adults is preliminary and hasn't been replicated at scale. The clinical literature is more robust than most research-chemical peptides, but it doesn't support broad outcome claims.

Animal evidence: Consistent with GHRH pharmacology; multiple rodent studies document GH axis activation and downstream effects.

Anecdotal community reports: Users frequently describe Sermorelin as a lower-risk entry point into GH-axis research, with the compounding pharmacy pathway seen as a meaningful quality assurance advantage. Reports of clinically meaningful body composition changes are mixed.

GHRP-2 - Evidence Summary

Human trial evidence: GHRP-2 has one of the more extensive human pharmacology datasets among synthetic GHRPs. Peer-reviewed trials document acute GH pulse stimulation in both healthy adults and individuals with GH deficiency. Concomitant prolactin and cortisol elevations are documented in the same human studies - this is a consistent finding, not a speculation, and should factor into any research interpretation.

Animal evidence: Extensive. Rodent, ovine, and bovine models have been used to characterise GHS-R1a agonism, GH pulsatility, and anabolic effects.

Anecdotal community reports: Self-experimental reports describe strong acute GH effects but also consistent appetite stimulation and more frequent cortisol-related side effects (irritability, sleep disruption) compared to Ipamorelin. Some users employ GHRP-2 specifically for the appetite-stimulating effect.

Hexarelin - Evidence Summary

Human trial evidence: Hexarelin has published human pharmacology data, including studies suggesting it produces among the highest GH pulse amplitudes of any synthetic GHRP tested in human subjects. Cardioprotective effects hypothesised from GHS-R1a and CD36 dual agonism are almost entirely animal-model derived - there are no robust human RCTs supporting cardiac outcome claims.

Animal evidence: Strong for GH stimulation; reasonably characterised for cardiac effects in rodent ischemia/reperfusion models. These findings are mechanistically interesting but haven't translated to human endpoints.

Anecdotal community reports: Users frequently note rapid tolerance development (tachyphylaxis) with continuous use - consistent with published animal data on desensitisation. This limits its practical utility in sustained research protocols compared to Ipamorelin.

MK-677 (Ibutamoren) - Evidence Summary

Human trial evidence: MK-677 is the standout exception in this category: multiple completed double-blind, placebo-controlled human trials with published outcomes. Studies in elderly adults (Nass et al., *Annals of Internal Medicine*, 2008, n=65 at one year; earlier Copinschi et al. data) document robust GH and IGF-1 elevation, improved slow-wave sleep, and lean mass preservation. The same trials document meaningful impairment of insulin sensitivity - a finding that's consistent across multiple studies and not trivial.

Animal evidence: Extensive, consistent with the human data.

Anecdotal community reports: Very large community experience base. Appetite stimulation and water retention are consistently reported adverse effects. The oral route is frequently cited as a key practical advantage over injectable peptides.

IGF-1 LR3 - Evidence Summary

Human trial evidence: Near-absent for the LR3 variant specifically. Native IGF-1 has a clinical literature (including in GH deficiency and Laron syndrome), but IGF-1 LR3 as administered in research-chemical contexts lacks formal Phase I/II human trial data at relevant doses. Any evidence extrapolated from native IGF-1 studies should be treated with significant caution given the structural differences.

Animal evidence: Extensive preclinical interest across muscle wasting, metabolic syndrome, wound healing, and neurological models. The mechanism is exceptionally well-characterised at the receptor level.

Anecdotal community reports: Community reports describe pronounced acute effects - including significant hypoglycaemia events - and are frequently associated with more serious adverse event narratives than the GHRH/GHRP class. The risk signal from self-experimental reports is meaningfully elevated relative to the upstream secretagogues.

Follistatin 344 - Evidence Summary

Human trial evidence: Zero peer-reviewed human evidence for exogenous recombinant Follistatin 344 administration at doses circulating in the research-chemical community. Human gene-therapy safety data exists from distinct clinical contexts and can't be extrapolated to subcutaneous recombinant protein injection.

Animal evidence: Rodent and primate myostatin inhibition studies are among the more compelling animal-model muscle data in this space. The mechanistic rationale is peer-reviewed and established.

Anecdotal community reports: Sparse and difficult to authenticate, partly because recombinant protein products are extremely difficult for end users to verify. Reports of dramatic muscle hypertrophy circulate but are unverified and methodologically uninterpretable.

---

Where IGF-1 LR3 Fits - and Why It Represents a Distinct Risk Category

This warrants separate treatment because the risk architecture of IGF-1 LR3 is qualitatively different from the GHRH/GHRP compounds above it.

The GHRH analogs and GHRPs covered above all work by stimulating the pituitary to release endogenous GH within the existing feedback architecture. If GH rises too high, somatostatin tone increases, the pituitary reduces secretion, and the system self-corrects to a degree. That feedback loop is imperfect and can be overridden with aggressive dosing, but it exists.

IGF-1 LR3 has no such feedback governor. It directly activates IGF-1 receptors in peripheral tissue. IGF-1R shares downstream signalling with the insulin receptor (particularly the PI3K/Akt pathway), which explains the hypoglycaemia risk - this isn't a rare idiosyncratic reaction but a predictable pharmacodynamic consequence of the mechanism. Hypoglycaemia events severe enough to cause loss of consciousness have been reported in community self-experimental contexts.

More significantly for long-term risk, IGF-1R is a receptor tyrosine kinase that drives cellular proliferation. The epidemiological association between elevated IGF-1 and cancer risk - particularly colorectal, prostate, and breast - is documented in observational literature. This doesn't establish causation at research-peptide doses, but the mitogenic signal from sustained IGF-1R activation isn't a theoretical concern. Individuals with pre-existing or undiagnosed neoplasia who administer IGF-1 LR3 are at genuinely elevated risk of accelerating disease progression.

Research context note: IGF-1 LR3 has legitimate preclinical scientific interest, and researchers in controlled laboratory settings use it appropriately in in vitro and animal models. The risk profile described above applies specifically to unsupervised human self-administration - the context where it's most frequently encountered outside academic settings.

---

Comparator Compounds: MK-677, GHRP-2, Hexarelin, and Tesamorelin as Research Alternatives

The GH-axis peptide space extends well beyond the four core compounds in this guide's title. Understanding where the alternatives sit mechanistically is useful for research context.

MK-677 (Ibutamoren) is a non-peptide GHS-R1a agonist - effectively an orally bioavailable GHRP mimetic. Its double-blind human trial evidence base makes it genuinely distinctive in this category. The tradeoff is a pronounced side-effect profile (insulin resistance, appetite stimulation, water retention) and near-complete absence of pulsatility: MK-677 produces more sustained GH elevation rather than discrete pulses characteristic of injectable GHRPs, which some researchers view as less physiologically appropriate.

GHRP-2 sits mechanistically adjacent to Ipamorelin but with a materially different neuroendocrine side-effect profile. Human studies document prolactin and cortisol co-elevation. Its lower price point and documented acute GH pulse data make it a common reference compound in research protocols, but the endocrine off-target effects complicate interpretation of results attributed to GH alone.

Hexarelin is of particular research interest for its CD36 agonism and associated cardiac pharmacology, which is distinct from any other compound in this guide. That said, its tachyphylaxis pattern and cortisol/prolactin co-elevation limit its utility in sustained GH-stimulation protocols. The cardiac research signal is compelling in animal models and awaits human translational work.

Tesamorelin is a GHRH analog approved by the FDA for HIV-associated lipodystrophy - making it one of the few compounds in this class with both regulatory approval and a specific human indication. That approval doesn't extend to general body composition applications, but the human clinical database (including documented effects on visceral adiposity) is more robust than most research-chemical GHRH analogs.

Follistatin 344 is included here but sits in a separate mechanistic category entirely - it's not a GH-axis compound but a myostatin-binding protein. Its inclusion reflects the research community's tendency to combine it with GH-axis peptides in self-experimental protocols. The evidentiary basis for this combination is essentially zero in humans, and the authentication and contamination risks associated with recombinant protein products from research-chemical vendors are among the highest in this market.

---

Dosing Ranges Reported in Research Contexts (Not Recommendations)

> Critical disclaimer: The following figures are drawn from published research literature and do not constitute dosing recommendations. These compounds are not approved for human use in most jurisdictions. Administration outside of a supervised research or clinical context carries unquantified risk. Consult a licensed healthcare provider before considering any peptide administration.

CJC-1295 (DAC form)

Published Phase II data used doses of 30, 60, 120, and 300 mcg/kg in single-injection protocols. Community self-experimental protocols frequently reference 1-2 mg subcutaneous injection 1-2 times weekly, though this falls outside formal trial parameters and lacks controlled safety data at those frequencies.

CJC-1295 without DAC (Mod GRF 1-29)

Research protocols referencing the non-DAC form typically cite 100-300 mcg per injection, administered 2-3 times daily given the shorter half-life. This is consistent with the short-duration GHRH stimulation the compound is designed to produce.

Ipamorelin

Animal pharmacology studies characterised doses in the microgram-per-kilogram range. Community protocols reference 100-300 mcg per injection, typically 2-3 times daily, often co-administered with CJC-1295 without DAC. No robust human dose-finding trials for body composition endpoints in healthy adults have been published.

Sermorelin

Licensed clinical use in the US was at doses of 0.03 mg/kg subcutaneously for diagnostic purposes, with therapeutic protocols varying. Compounding pharmacy formulations exist in the US; dosing in that context is the domain of the prescribing physician, not a research-context summary.

GHRP-2

Published human studies have used acute doses in the 1 mcg/kg range (intravenous) for GH stimulation testing. Community self-experimental protocols report 100-300 mcg subcutaneous injection 2-3 times daily, consistent with the compound's short half-life.

Hexarelin

Human pharmacology studies characterised GH responses at doses of 1-2 mcg/kg intravenously. Community protocols are broadly similar to other GHRPs: 100-200 mcg per injection with frequency limited by documented tachyphylaxis.

MK-677

Human trials have used oral doses of 10-50 mg/day. The Nass et al. (2008) trial used 25 mg/day. Insulin sensitivity impairment has been documented at these doses.

IGF-1 LR3

Formal human dose-finding data for this compound doesn't exist in the published literature at relevant community-used doses. Community protocols report 20-100 mcg/day subcutaneous or intramuscular injection, with cycles typically limited to 4-6 weeks given hypoglycaemia risk. Hypoglycaemia monitoring would be an absolute requirement in any research protocol involving this compound in biological systems.

Follistatin 344

No validated human dosing protocol exists in peer-reviewed literature. Community reports describe doses in the 50-200 mcg range administered subcutaneously or intramuscularly. The lack of validated pharmacokinetic data in humans makes these figures uninterpretable in a research context.

---

Reported Side Effects and Contraindications Across the Stack

CJC-1295

Reported in human trials and community self-reports: transient flushing and tingling at injection, headache, water retention, and injection-site reactions. Sustained IGF-1 elevation over multi-week protocols raises theoretical concerns about acromegaloid effects (joint discomfort, soft tissue swelling, carpal tunnel-like symptoms) and insulin sensitivity - though these aren't formally characterised at community doses. The extended half-life complicates adverse event management: effects can't be rapidly cleared by stopping administration.

Ipamorelin

Reported in community self-reports: headache, flushing, transient nausea, and mild water retention. The selectivity profile (minimal cortisol/prolactin elevation) is its key differentiator from earlier GHRPs. Injection-site reactions and cold-chain management failures are practical adverse event sources in non-laboratory settings.

Sermorelin

Similar to CJC-1295 in terms of GH-axis effects, but the shorter half-life limits accumulation. Reported side effects include injection-site reactions, flushing, headache, and nausea. The short clearance profile is an advantage if adverse effects occur.

GHRP-2

Human trials document prolactin and cortisol elevation alongside GH stimulation - this is a characterised pharmacological finding, not speculation. Appetite stimulation is consistent. Short half-life is practically relevant to side-effect management.

Hexarelin

Cortisol and prolactin elevation documented in human studies. Rapid tachyphylaxis with continuous use limits clinical utility. Cardiac effects observed in animal models require human study before conclusions can be drawn - neither the cardioprotective claims nor the cardiac safety profile is established in humans.

MK-677

Insulin resistance is documented in multiple human trials - not a rare adverse event but a consistent pharmacodynamic effect. Water retention, appetite stimulation, and transient morning lethargy are commonly reported. It's not appropriate for individuals with pre-existing insulin resistance or type 2 diabetes risk factors without medical supervision.

IGF-1 LR3

Hypoglycaemia is the most acute risk - structurally inherent, not dose-dependent in a simple linear sense, and potentially severe. Mitogenic signalling at IGF-1R creates a theoretically serious risk in the presence of undiagnosed or pre-existing malignancy. Lipohypertrophy at injection sites has been reported in community contexts. This compound has the most serious risk profile of any compound in this guide.

Follistatin 344

FSH suppression and broader reproductive endocrine disruption are documented in animal models. Endotoxin contamination risk from lower-tier vendors is a practical concern for recombinant protein products. The actual side-effect profile in humans at community doses is essentially uncharacterised.

General contraindications across GH-axis peptides: Active malignancy (or history of malignancy) is the broadest contraindication - GH and IGF-1 axis stimulation in the presence of malignant tissue isn't appropriate. Diabetes or clinically significant insulin resistance is a relative contraindication, particularly for MK-677 and IGF-1 LR3. Pregnancy and breastfeeding are absolute contraindications. Active pituitary pathology requires medical evaluation before any GHRH/GHRP use.

---

Legal and Regulatory Status by Region: US, UK, EU, and Australia

United States

• CJC-1295, Ipamorelin, GHRP-2, Hexarelin, IGF-1 LR3, Follistatin 344, MK-677: Not FDA-approved for human use. Sold as research chemicals for in vitro and animal research. Not scheduled controlled substances under the CSA in most formulations, but recent FDA enforcement has targeted compounding pharmacies and some vendors. No legal pathway for human administration outside an IND.
• Sermorelin: Has a US compounding pharmacy pathway as a prescription compound. The former brand (Geref) is no longer commercially available, but compounding pharmacies licensed for sterile preparations can produce it on prescription. This is a legitimate, physician-supervised pathway not available to the other compounds in this guide.

United Kingdom

• CJC-1295, Ipamorelin, GHRP-2, Hexarelin, IGF-1 LR3, Follistatin 344, MK-677, Sermorelin: None are MHRA-licensed for human use. Peptides not covered under the Misuse of Drugs Act are technically legal to possess for personal use in many forms, but selling them for human consumption is likely to trigger Medicines Act provisions. The legal position for research chemicals sold 'not for human use' is a grey area that has been subject to increasing MHRA scrutiny. The UK customs framework also creates import risk.

European Union

• Status varies by member state. Some countries (Germany, Sweden, France) apply strict medicines regulations that effectively prohibit unlicensed peptide sales regardless of research-chemical framing. No EMA marketing authorisation exists for any of these compounds in the GH-axis research space. Importation for personal use is treated inconsistently across customs jurisdictions.

Australia

• All compounds in this guide are likely captured by the Therapeutic Goods Administration (TGA) scheduling framework. MK-677 is a Schedule 4 substance (prescription only). Most injectable peptides are Schedule 4 or higher. Importation for personal use without a valid prescription from a TGA-approved product is illegal. Australian enforcement has been meaningfully active in the peptide space, with known seizures at customs. This is one of the stricter jurisdictions globally for research-chemical peptide access.

---

Sourcing Considerations: COA Standards, Red Flags, and the DAC Labelling Problem

What a Credible COA Should Include

A Certificate of Analysis from a reputable vendor should include: identity confirmation via HPLC or mass spectrometry with the specific peptide sequence identified, purity percentage (95%+ is a reasonable minimum standard for research use, with many credible vendors now publishing 98%+ results), endotoxin testing results (particularly critical for injectable compounds), residual solvent analysis, and microbial contamination screening. The COA should reference an independent third-party laboratory, not an in-house analytical facility - vendor-produced COAs carry obvious conflicts of interest and aren't appropriate for research procurement decisions.

The DAC Labelling Problem

The CJC-1295 market has an endemic mislabelling problem worth flagging specifically. 'CJC-1295 with DAC' and 'CJC-1295 without DAC' (Mod GRF 1-29) are pharmacologically distinct compounds with different half-lives, dosing frequencies, and GH pulsatility profiles. Vendors frequently mislabel one as the other, sometimes through genuine formulation confusion and sometimes through deliberate misrepresentation. The DAC moiety is detectable via mass spectrometry - a COA that doesn't include MS identity confirmation for CJC-1295 products should be viewed with significant scepticism. If purchasing CJC-1295, verifying DAC presence or absence through third-party analytical data is a minimum research quality standard.

Red Flags in Vendor Selection

• No COA available, or COA is not from an identifiable independent laboratory
• No age verification or ID check required for purchase
• Claims of clinical efficacy or direct health benefits in product listings
• Pricing significantly below market rate (recombinant proteins like Follistatin 344 and IGF-1 LR3 have meaningful synthesis costs - dramatically low prices suggest impure or mislabelled product)
• No cold-chain shipping documentation for peptides requiring refrigeration
• No sterility testing results for injectable preparations

Follistatin 344 and IGF-1 LR3: Elevated Authentication Risk

Recombinant proteins are categorically harder to authenticate than synthetic peptides. The production complexity of correctly folded recombinant proteins means substitution with cheaper proteins, endotoxin contamination, and misfolding are materially higher risks than with synthetic peptides like CJC-1295 or Ipamorelin. Research procurement of these compounds from the commercial research-chemical market should be treated with heightened scepticism, and COA review should be rigorous.

---

Regulatory Disclaimer and Research-Chemical Legal Status

All peptide compounds covered in this guide, with the exception of Sermorelin through its US compounding pharmacy pathway, are research chemicals sold for in vitro and animal research use only. They are not approved by the FDA, MHRA, EMA, or TGA for human therapeutic or prophylactic use. Peptide Guides is a research-aggregator publication. Nothing in this guide constitutes medical advice, a treatment recommendation, or an endorsement of human self-administration. Individuals considering any of these compounds for human use should consult a licensed physician. Regulatory status varies by jurisdiction and may change; readers are responsible for verifying local legal status before procurement or use.

---

Where to Learn More: PubMed and ClinicalTrials.gov Pointers

• CJC-1295 human pharmacokinetics: Search PubMed for 'CJC-1295 growth hormone pharmacokinetics' - the Ionescu and Frohman 2006 JCEM paper is the primary reference.
• Ipamorelin pharmacology: Search PubMed for 'ipamorelin ghrelin receptor selectivity' - Raun et al. 1998 in *European Journal of Endocrinology* is foundational.
• MK-677 human trials: Search PubMed for 'ibutamoren mesylate growth hormone' or 'MK-677 clinical trial'. Nass et al. 2008 in *Annals of Internal Medicine* is the largest published trial.
• GHRH + GHRP synergy: Search PubMed for 'GHRH GHRP synergy growth hormone' - Bowers et al. and subsequent work characterise the supra-additive GH release.
• IGF-1 cancer risk: The IARC and multiple observational cohort studies on IGF-1 and cancer risk are available via PubMed search for 'IGF-1 cancer risk cohort'.
• ClinicalTrials.gov: Search 'sermorelin', 'tesamorelin', and 'ibutamoren' for registered and completed trials. The GHRH/GHRP research-chemical compounds (CJC-1295, Ipamorelin) have minimal registered trial activity.
• Tesamorelin (approved context): FDA prescribing information for Egrifta is publicly available and provides a useful comparator for what legitimate GH-axis clinical data looks like at a regulatory standard.